Immediate Impact
5 from Science/Nature 72 standout
Citing Papers
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
Works of Nathan Winslow being referenced
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
2018
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Nathan Winslow | 74 | 63 | 55 | 190 | 84 | 3 | 359 | |
| D Stablein | 46 | 114 | 81 | 69 | 113 | 10 | 387 | |
| Gloriana Shelton | 15 | 10 | 161 | 119 | 58 | 5 | 368 | |
| G. Salama | 55 | 47 | 28 | 44 | 109 | 9 | 377 | |
| Barbara F. Ngudiankama | 28 | 39 | 65 | 81 | 37 | 6 | 325 | |
| Luc Marcelis | 95 | 78 | 119 | 49 | 62 | 8 | 383 | |
| Donna Marie L. Alvino | 57 | 129 | 54 | 128 | 112 | 11 | 360 | |
| Alexander Farahani | 61 | 27 | 56 | 106 | 51 | 7 | 359 | |
| P. Chikoti | 56 | 128 | 91 | 113 | 27 | 8 | 371 | |
| Rong Xu | 25 | 31 | 46 | 133 | 19 | 9 | 397 | |
| Margareta Nordin | 70 | 20 | 172 | 58 | 9 | 10 | 328 |
All Works
Loading papers...